The research, led by James D. Sargent of Dartmouth College’s Geisel School of Medicine, set out to correct what the authors see as a systematic blind spot in decades of prior work. Most earlier studies measured smoking narrowly — often comparing only current smokers with former or never smokers — and frequently included young adults, in whom the effects of smoking on quality of life are still small. Worse, many analyses statistically adjusted for smoking-related diseases such as cancer, cardiovascular disease, and chronic lung disease. But those diseases lie on the causal pathway between smoking and diminished wellbeing, the authors argue, so adjusting for them effectively erases much of smoking’s true impact before the analysis even begins.

To capture the full burden, the team constructed an 11-point lifetime cigarette smoke exposure index, or LCSEI, drawing on data from Wave 5 of the Population Assessment of Tobacco and Health (PATH) Study, collected in 2018 and 2019. The index combined five components: current smoking status, the heaviness of current smoking, cumulative pack-years of smoking, whether a person started smoking before age 15, and weekly hours of exposure to secondhand smoke. A score of zero represents a never-smoker with no secondhand exposure, while a score of 11 describes a heavy current smoker who began in childhood, accumulated more than 40 pack-years, and spends more than 20 hours a week breathing other people’s smoke.

The study sample comprised 7,001 adults aged 40 and older, weighted to represent the US population. In this group, 6.7 percent had smoked during childhood and 16.9 percent were current smokers, with 10 percent smoking more than 20 cigarettes a day. Among those who had ever smoked, the average pack-year total was 32.9, and more than one in five had amassed more than 40 pack-years. Quality of life was measured with the PROMIS Global-10 questionnaire, which yields separate scores for global physical health and global mental health, both validated against the widely used EuroQOL-5D instrument.

The results showed a strikingly clean pattern: both physical and mental quality-of-life scores declined in a nearly perfect linear fashion as lifetime smoke exposure rose. In the bivariable analysis, each additional point on the index corresponded to a loss of roughly 0.28 points in physical health scores and 0.30 points in mental health scores. After adjusting for age, gender, race, income, education, geography, body mass index, and weekly exercise, the association remained robust, with each point on the index costing about 0.20 points of physical and 0.22 points of mental quality of life — a magnitude similar to that associated with a decade of aging, being female for mental health, or dropping one income category.

The headline finding comes from comparing the extremes. Adults at the highest possible exposure score had mean global physical health 14.5 percent lower, and global mental health 15.2 percent lower, than those at the lowest score. By contrast, the difference between adults who had not finished high school and those holding a bachelor’s or advanced degree amounted to only 3.0 percent for physical and 5.3 percent for mental health. The gap between households earning under $25,000 a year and those earning $100,000 or more was 10.9 percent and 11.4 percent — meaning lifetime smoking exposure carries a burden that rivals poverty itself, and far exceeds the burden of low educational attainment.

The team ran a series of sensitivity analyses to test whether the findings could be artifacts. When respondents with incomplete smoking histories — about 82 percent of the originally excluded cases — were added back into the models, the results barely moved. An E-value analysis, which quantifies how strong unmeasured confounding or misclassification would need to be to explain away an association, yielded a value of 4.29 for the lower confidence bound, a level generally considered to require implausibly strong bias to account for the observed effect. And when the researchers added an 18-item index of smoking-related diseases — including COPD, diabetes, cancer, heart failure, and stroke — the smoking association shrank by roughly half but remained statistically significant, confirming that chronic disease mediates much, but not all, of smoking’s impact on wellbeing.

That residual association is intriguing in itself. It could reflect concurrent effects of cigarette smoke on the body that operate independently of diagnosed disease, or damage from smoke exposure during adolescent development that shapes how adults perceive their own health decades later. Previous work by some of the same researchers found that childhood smoking onset is associated with chronic obstructive pulmonary disease independent of pack-years and current smoking intensity, lending plausibility to the idea that early-life exposure leaves marks that persist even after accounting for total dose. The authors call for more research to disentangle these mechanisms.

Perhaps the most consequential implication concerns inequality. Smoking prevalence follows a well-documented socioeconomic gradient, with lower-income adults smoking at higher rates and accumulating more lifetime exposure. The new findings suggest that disadvantage delivers a double blow to quality of life: directly, through the material hardships of poverty, and indirectly, through greater lifetime exposure to cigarette smoke. Framed this way, tobacco control is not merely a public health measure but an equity intervention — one whose benefits would flow disproportionately to older adults already bearing the heaviest burdens of poor health.

The study does carry limitations. It is cross-sectional, so it captures a single moment in time, and it relies on retrospective recall of smoking behavior reaching back to childhood. The authors point to multiple validation studies showing that recalled smoking histories, while imperfect at the individual level, are not systematically linked to health outcomes, meaning such errors would tend to shrink rather than inflate observed associations. Loss to follow-up and missing item responses also trimmed the analytic sample, though sensitivity analyses that restored most missing cases left the primary findings intact. Even with those caveats, the message is stark: for older Americans, a lifetime of cigarette smoke has quietly exacted a price on daily wellbeing that rivals poverty itself — and the surest way to promote healthy aging, the authors conclude, is to eliminate cigarettes altogether.

Subject of Research: Association between lifetime cigarette smoke exposure and health-related quality of life among older US adults

Article Title: Comprehensive assessment of lifetime cigarette smoking and its association with health-related quality of life among older US adults

Article References: Sargent, J. D., Ozga, J. E., Stanton, C. A., Tang, Z., & Paulin, L. M. (2026). Comprehensive assessment of lifetime cigarette smoking and its association with health-related quality of life among older US adults. PLOS Aging and Health, 1(3), e0000043. https://doi.org/10.1371/journal.page.0000043

Image Credits: AI Generated

DOI: 10.1371/journal.page.0000043

Keywords: cigarette smoking, quality of life, healthy aging, PATH Study, secondhand smoke, pack-years, health disparities, PROMIS, tobacco control, socioeconomic inequality, chronic disease, older adults

The study, published in Holistic Integrative Oncology, drew on five cycles of the National Health and Nutrition Examination Survey, or NHANES, the rolling federal program that collects standardized laboratory measurements from a cross-section of the civilian, noninstitutionalized US population. The researchers assembled a final analytic population of 7,174 men with concurrent measurements of serum cotinine, total PSA, and free PSA. The free-to-total PSA ratio, a value clinicians use to sharpen the interpretation of borderline PSA results, was calculated directly from the two measured fractions. Cotinine, measured with isotope dilution high-performance liquid chromatography coupled to atmospheric pressure chemical ionization tandem mass spectrometry, served as the objective window onto recent nicotine exposure — capturing not only active smoking but also secondhand smoke and other nicotine sources that self-reported questionnaires routinely miss or misclassify.

What the analysis found was a story of two biomarkers going their separate ways. In fully adjusted multivariable linear regression models that accounted for age, race and ethnicity, body mass index, education, marital status, estimated kidney function, alcohol use, family income, and survey cycle, serum cotinine showed essentially no independent association with total PSA — the regression coefficient hovered at effectively zero, with a P value of 0.801. Yet the same exposure variable was consistently and significantly associated with a lower free-to-total PSA ratio: each additional nanogram per milliliter of cotinine corresponded to a decrease of roughly 0.005 percentage points in the ratio (95% confidence interval -0.00705 to -0.00283; P = 0.000005). The signal survived every tier of statistical adjustment, growing rather than shrinking as confounders were layered in, and the direction remained consistent when cotinine was log-transformed to temper the influence of heavy smokers.

The discordance between the two endpoints is what makes the result scientifically interesting. Total PSA reflects the overall circulating concentration of a kallikrein-related serine protease secreted by the androgen-responsive prostate gland, a concentration that climbs with benign prostatic hyperplasia, prostatitis, and prostate cancer alike. The free-to-total ratio, by contrast, depends not on how much PSA is in the blood but on how it is distributed between molecular forms — free PSA floating unbound versus PSA complexed with proteins such as alpha-1-antichymotrypsin. Because the two endpoints track different aspects of PSA chemistry, a compound that shifts the composition of circulating PSA without changing its total concentration would produce exactly the pattern observed: a null association with total PSA and a robust inverse association with the ratio.

Recognizing that a single cotinine measurement captures only a narrow biological window — days, not decades — the team added a second exposure dimension. From self-reported cigarette histories, they calculated pack-years, the classic epidemiological measure of cumulative smoking burden, for 6,132 of the participants, 3,433 of whom were current or former smokers. Correlation analyses confirmed that cotinine and pack-years point in the same direction but are far from interchangeable: the Pearson correlation between raw values was a modest 0.209, the Spearman rank correlation 0.270, and only after log-transforming both variables did the relationship strengthen to 0.337. A heavy lifetime smoker who quit years ago can carry low cotinine today; a recent relapser can carry high cotinine on a thin lifetime foundation. The two metrics measure genuinely different things.

That difference mattered in the sensitivity models. When pack-years replaced cotinine as the exposure variable in fully adjusted regressions, the association with PSA ratio vanished entirely (β = -0.00750, 95% CI -0.02010 to 0.00509; P = 0.243), and the log-transformed version of pack-years fared no better. The cotinine signal, in other words, cannot be explained away as a shadow of lifetime cigarette burden. One provocative secondary pattern emerged for total PSA: log-transformed pack-years showed a statistically significant inverse association in sensitivity analyses, hinting that decades of cumulative exposure may relate to total PSA through chronic tissue, vascular, or endocrine remodeling in ways that an acute biomarker cannot capture. The authors are careful to stress that nothing in these data should be read as evidence that smoking protects the prostate — tobacco exposure has established harmful effects across organ systems and is associated with worse outcomes after prostate cancer diagnosis, including higher mortality and progression risk.

What might cotinine actually be doing to PSA chemistry? The mechanistic clues point toward nicotinic acetylcholine receptor signaling and androgen biology. Cotinine, which persists in serum far longer than nicotine, binds cell-surface cholinergic alpha5 nicotinic receptors, which experimental studies have shown are upregulated in prostate cancer and drive tumor cell proliferation and invasion. Experimental work also suggests cotinine can interact with the androgen receptor and suppress its expression in animal prostate tissue. Because PSA secretion is androgen-regulated, cotinine-related modulation of androgen receptor signaling could preferentially reduce the epithelial secretion of free PSA, shifting a greater share of immunoreactive PSA toward the alpha-1-antichymotrypsin-complexed fraction — lowering the ratio while leaving total PSA nearly untouched. Tobacco-driven systemic inflammation could contribute as well by altering the acute-phase protein milieu in which PSA complexes circulate. These mechanisms remain inferential in a cross-sectional dataset, but they explain the observed geometry of the results with unusual precision.

The interpretation demands caution at every turn. NHANES participants were not enrolled because of suspected prostate disease, and no biopsy adjudication exists for this cohort, so the findings speak to biomarker-level variation in a general population, not to cancer incidence, diagnostic thresholds, or clinical decision-making. Serum cotinine is also shaped by CYP2A6-mediated metabolism, which varies across racial and genetic backgrounds, meaning identical cotinine values may reflect different actual nicotine intake. The authors noted that the cotinine-PSA ratio association appeared more pronounced in certain subgroups, including non-Hispanic White and non-Hispanic Black participants, men aged 40 to 49 and 70 to 79, and those with a body mass index above 18.5, but stratified patterns in cross-sectional data carry their own fragility. Smokers may also differ systematically in screening behavior, comorbidity, and healthcare access, and despite the standardized survey protocol, differential participation and missing laboratory data cannot be excluded as sources of selection.

Within those constraints, the study stakes out a genuinely novel position: it is, according to the authors, the first population-based analysis to link cotinine to prostate-related endpoints in a nationally representative sample. Its strength lies in the objective laboratory measurement of exposure, the large sample, and the statistical persistence of the PSA ratio association after extensive adjustment. Its limitation is time — a single cotinine measurement, a single PSA snapshot, and no way to order cause and effect. The authors call for longitudinal studies with repeated cotinine measurements, validated cumulative smoking metrics, nicotine metabolite profiling that includes trans-3′-hydroxycotinine, and adjudicated prostate disease outcomes to determine whether recent exposure status, cotinine metabolism, or something else entirely drives the association.

For clinicians and epidemiologists alike, the practical message is narrower than the biological one. Nothing in this analysis justifies changing PSA screening practice or interpreting an individual patient’s PSA ratio through the lens of a cotinine blood level. But the results do suggest that tobacco-related biological status is a real and quantifiable source of variation in one of the most widely used prostate biomarkers in medicine — a reminder that the numbers generated by screening assays are not static properties of a gland but dynamic readouts that absorb the chemical history of the person they come from. As molecular epidemiology continues to separate the recent exposure a biomarker captures from the cumulative burden a questionnaire recalls, studies like this one map the fault lines where those two measures diverge, and where the biology of tobacco meets the biochemistry of cancer screening.

Subject of Research: The association between serum cotinine, a biomarker of tobacco exposure, and prostate-related clinical endpoints including PSA measures

Article Title: Association between serum cotinine levels and prostate-related clinical endpoints

Article References: Wang, Z., Ge, Q., Anwaier, A., Xu, W., & Ye, D. (2026). Association between serum cotinine levels and prostate-related clinical endpoints. Holistic Integrative Oncology, 5(1), Article 76. https://doi.org/10.1007/s44178-026-00292-7

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00292-7

Keywords: serum cotinine, prostate-specific antigen, free-to-total PSA ratio, tobacco exposure, NHANES, prostate cancer, pack-years, nicotine metabolism, prostate biomarkers, epidemiology, urology, cancer screening